Alkermes (ALKS) Long-Term Investments (2011 - 2026)
Alkermes' (ALKS) quarterly Long-Term Investments came in at $26.4 million in Q1 2026, down 18.1% year-on-year from $32.2 million in Q1 2025, and up 18081.38% on a QoQ basis from $145000.0 in Q4 2025.
Alkermes (ALKS) Long-Term Investments (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Long-Term Investments data on file, last reported at $26.4 million in Q1 2026.
- On a quarterly basis, Long-Term Investments fell 18.1% year-over-year to $26.4 million in Q1 2026; TTM through Mar 2026 was $26.4 million, a 18.1% decrease from a year earlier, with the FY2025 full-year figure at $145000.0, down 99.8% from the prior year.
- Long-Term Investments for Q1 2026 stood at $26.4 million, up from $145000.0 in the prior quarter.
- Over the last five years, Long-Term Investments for ALKS reached as high as $229.8 million in Q1 2022 and fell as low as $145000.0 in Q4 2025.
- Historically, Long-Term Investments has averaged $81.8 million across 5 years, with a median of $73.1 million in 2024.
- Across the five-year window, Long-Term Investments jumped 165.85% in 2022 and plunged 99.8% in 2025, its largest moves.
- Year by year, Long-Term Investments stood at $131.6 million in 2022, then slumped by 69.69% to $39.9 million in 2023, then jumped by 83.39% to $73.1 million in 2024, then plunged by 99.8% to $145000.0 in 2025, then soared by 18081.38% to $26.4 million in 2026.
- Per Business Quant data, the three most recent Long-Term Investments figures were $26.4 million in Q1 2026, $145000.0 in Q4 2025, and $27.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 56.09 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 1.32 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 12.05 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 146.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | 26.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.36 Mn |
| Dec 31, 2025 | 145,000.00 |
| Sep 30, 2025 | 27.87 Mn |
| Jun 30, 2025 | 38.27 Mn |
| Mar 31, 2025 | 32.19 Mn |
| Dec 31, 2024 | 73.15 Mn |
| Sep 30, 2024 | 18.92 Mn |
| Jun 30, 2024 | 86.40 Mn |
| Mar 31, 2024 | 62.78 Mn |
| Dec 31, 2023 | 39.89 Mn |
| Sep 30, 2023 | 106.43 Mn |
| Jun 30, 2023 | 78.13 Mn |
| Mar 31, 2023 | 92.08 Mn |
| Dec 31, 2022 | 131.61 Mn |
| Sep 30, 2022 | 166.93 Mn |
| Jun 30, 2022 | 179.01 Mn |
| Mar 31, 2022 | 229.83 Mn |
| Dec 31, 2021 | 229.43 Mn |
| Sep 30, 2021 | 187.86 Mn |
| Jun 30, 2021 | 131.03 Mn |